Use of antithrombotic therapy in patients with hemophilia: a selected synopsis of the European Hematology Association - International Society on Thrombosis and Haemostasis - European Association for Hemophilia and Allied Disorders - European Stroke Organization Clinical Practice Guidance document
Journal of Thrombosis and Haemostasis · 2025
DOI: 10.1016/j.jtha.2024.10.033 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Miguel Escobar und 4 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas Health Science Center, Gulf States Hemophilia Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Hemophilia A, Thrombosis, Fibrinolytic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer, Amgen.
Themen: Schlaganfall
Abstract (Originalsprache)
Here, we summarize the European Hematology Association - International Society on Thrombosis and Haemostasis - European Association for Hemophilia and Allied Disorders - European Stroke Organization Clinical Practice Guidance document recommendations on antithrombotic therapy for cardiovascular indications among patients with hemophilia. This summary includes a discussion on primary and secondary prevention of venous and arterial thrombosis. The guidance document considers distinct and controversial challenges presented by various clinical scenarios in this aging patient population and provides thoughtful recommendations to assist the hemophilia care provider in clinical decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The University of Texas Health Science Center, Gulf States Hemophilia Center, Houston, Texas, USA.
- Department of Hematology, Coagulation Disorders, Helsinki University Hospital, Helsinki, Finland.
- Hematology-Oncology Clinical Research Group, St Michael's Hospital, Toronto, Ontario, Canada.
- King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
- Departments of Medicine and Laboratory Medicine and Pathobiology, St Michael's Hospital, Li Ka Shing Knowledge Institute, University of Toronto, Toronto, Ontario, Canada. Electronic address: Michelle.Sholzberg@unityheal…
Förderung
- Pfizer
- Amgen
Zitieren
APA
Escobar, M., Lassila, R., Bekdache, C., Owaidah, T., & Sholzberg, M. (2025). Use of antithrombotic therapy in patients with hemophilia: a selected synopsis of the European Hematology Association - International Society on Thrombosis and Haemostasis - European Association for Hemophilia and Allied Disorders - European Stroke Organization Clinical Practice Guidance document. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.10.033
Vancouver
Escobar M, Lassila R, Bekdache C, Owaidah T, Sholzberg M. Use of antithrombotic therapy in patients with hemophilia: a selected synopsis of the European Hematology Association - International Society on Thrombosis and Haemostasis - European Association for Hemophilia and Allied Disorders - European Stroke Organization Clinical Practice Guidance document. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2024.10.033
BibTeX
@article{Escobar2025,
author = {Escobar, Miguel and Lassila, Riitta and Bekdache, Carine and Owaidah, Tarek and Sholzberg, Michelle},
title = {Use of antithrombotic therapy in patients with hemophilia: a selected synopsis of the European Hematology Association - International Society on Thrombosis and Haemostasis - European Association for Hemophilia and Allied Disorders - European Stroke Organization Clinical Practice Guidance document},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
doi = {10.1016/j.jtha.2024.10.033}
}
EUVIMED